CoChat

Safety of injectable semaglutide for type 2 diabetes

Peter, Rajesh, Bain, Steve C. · 2020 · Expert Opinion on Drug Safety

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Semaglutide is the most recently approved injectable glucagon-like peptide-1 receptor agonist (GLP-1RA) for people with type 2 diabetes (T2DM). It is one of the three currently marketed GLP-1RAs that can be administered once weekly. AREAS COVERED: This review focusses on the safety of injectable semaglutide. Semaglutide has been assessed in the SUSTAIN phase 3 clinical trial programme, which included patients across the disease spectrum, i.e. treatment-naïve to those receiving insulin. The authors have looked at all published literature on safety considerations of once weekly GLP-1RA with particular reference to semaglutide. EXPERT OPINION: Semaglutide is the most powerful injectable GLP-1RA. The cardiovascular (CV) outcome trial (SUSTAIN 6) showed CV superiority and its adverse event profile is as expected for the GLP-1RA class with predominantly gastrointestinal side-effects. Concerns about the thyroid and pancreatic safety have not been substantiated. There is no indication of renal or liver harm for semaglutide. Data consistent with reno-protection and benefit in liver disease is presented. There is a modest signal for increased gall bladder adverse events. An increase in diabetic retinopathy (DR) events in the SUSTAIN 6 trial is the most concerning safety signal. Caution regarding DR is needed when initiating semaglutide and recommendations are suggested.

Overview

Integrity signals

Registry

Crossref · 10.1080/14740338.2020.1772230

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 76 references

Research works printed but not linked: 6

  1. Centers for Disease Control and Prevention, 2011, National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States
  2. 2008, Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
  3. 2012, Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
  4. 2012, LiverTox: clinical and research information on drug-induced liver injury [Internet]
  5. O’Neil PM, Lancet. 2018, 392, 637
  6. 2006, Drugs and lactation database (LactMed) [Internet]

Cited by

See all 17

Metadata

Authors
Peter, R., & Bain, S. C.
Affiliations
  • Swansea Bay University Health Board (GB)
  • Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK
Venue
Expert Opinion on Drug Safety
Published
2020-06-04
Volume
19
Issue
7
Pages
785-798
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W3027159009
Cited by
17
References
76
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1
FWCI
1.89
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, type 2 diabetes, GLP-1 receptor agonists, drug safety, SUSTAIN trials, cardiovascular outcomes, gastrointestinal adverse effects, renal protection, liver disease, diabetic retinopathy
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of injectable semaglutide for type 2 diabetes. https://app.cochat.ai/papers/10.1080/14740338.2020.1772230
The paper
Peter, R., & Bain, S. C. (2020). Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2020.1772230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.